Cargando…

Acquired latent tuberculosis infection in psoriasis patients treated with etanercept in the People’s Republic of China

BACKGROUND: TNF-α plays a key role in host defense against mycobacterial infection, and patients receiving TNF-α blocker treatment have increased susceptibility to tuberculosis disease. In the People’s Republic of China, an intermediate tuberculosis-burden country, the latent tuberculosis infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Cheng-Rang, Mao, Qiu-Xia, Chen, Min, Jia, Wei-Xue, Yao, Xu, Feng, Su-Ying, Jia, Hong, Gong, Juan-Qin, Yang, Xue-Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610804/ https://www.ncbi.nlm.nih.gov/pubmed/26508833 http://dx.doi.org/10.2147/DDDT.S87260

Ejemplares similares

Glomerular filtration rate in patients with psoriasis treated with etanercept
por: Gisondi, Paolo, et al.
Publicado: (2016)

Etanercept in the treatment of plaque psoriasis
por: Nguyen, Thao U, et al.
Publicado: (2009)

The safety of etanercept for the treatment of plaque psoriasis
por: Papp, Kim A
Publicado: (2007)

Etanercept in the Treatment of Generalized Annular Pustular Psoriasis
por: Lo Schiavo, Ada, et al.
Publicado: (2012)

Etanercept in psoriasis: the evidence of its therapeutic impact
por: Thomson, Andrew
Publicado: (2007)

Multidrug-Resistant Tuberculosis, People’s Republic of China, 2007–2009
por: He, Guang Xue, et al.
Publicado: (2011)

Use of etanercept for psoriasis in a liver transplant recipient
por: Madankumar, Reshmi, et al.
Publicado: (2015)

Effects of methotrexate and etanercept treatment in moderate and severe psoriasis
por: Benites, Elizabeth, et al.
Publicado: (2022)

Co-endemicity of Pulmonary Tuberculosis and Intestinal Helminth Infection in the People’s Republic of China
por: Li, Xin-Xu, et al.
Publicado: (2016)

Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept
por: Choi, Chong Won, et al.
Publicado: (2019)

Etanercept, improved dosage schedules and combinations in the treatment of psoriasis: an update
por: Segaert, Siegfried
Publicado: (2009)

Relationship between etanercept and thyroid function in patients with psoriasis vulgaris
por: ROMAN, IULIA IOANA, et al.
Publicado: (2018)

Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports
por: De Simone, Clara, et al.
Publicado: (2016)

Paradoxical SAPHO Syndrome after Etanercept in a Patient with Psoriasis
por: Gimeno-Castillo, Javier., et al.
Publicado: (2022)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

Efficacy and Safety of Secukinumab in Patients with Plaque Psoriasis and Latent Tuberculosis
por: Ribero, Simone, et al.
Publicado: (2019)

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
por: Kivelevitch, Dario, et al.
Publicado: (2014)

Long-term safety of etanercept in psoriasis: Retrospective study focused on infections
por: Orsini, Diego, et al.
Publicado: (2016)

Identification potential biomarkers in pulmonary tuberculosis and latent infection based on bioinformatics analysis
por: Qin, Xue-Bing, et al.
Publicado: (2016)

Frequency of tuberculosis among diabetic patients in the People’s Republic of China
por: Wang, Hong-Tian, et al.
Publicado: (2014)

A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy
por: Colombo, Giorgio L, et al.
Publicado: (2009)

Nodular Vasculitis That Developed during Etanercept (Enbrel) Treatment in a Patient with Psoriasis
por: Park, Seung-Bae, et al.
Publicado: (2015)

Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab
por: Brunner, P.M., et al.
Publicado: (2021)

Etanercept alleviates psoriasis by reducing the Th17/Treg ratio and promoting M2 polarization of macrophages
por: Li, Xiaoqing, et al.
Publicado: (2022)

Spatial variations of pulmonary tuberculosis prevalence co-impacted by socio-economic and geographic factors in People’s Republic of China, 2010
por: Li, Xin-Xu, et al.
Publicado: (2014)

Risk of latent tuberculosis infection in children living in households with tuberculosis patients: a cross sectional survey in remote northern Lao People's Democratic Republic
por: Nguyen, Tuan H, et al.
Publicado: (2009)

The Challenging Evaluation of Patients with Severe Psoriasis for Latent Tuberculosis: An Important Indication for IGRA
por: Katsenos, Stamatis, et al.
Publicado: (2011)

Interstitial granulomatous dermatitis successfully treated with etanercept
por: Ahmed, Zavier Shawkat, et al.
Publicado: (2014)

Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment
por: Boggs, Robert L, et al.
Publicado: (2014)

Long-Term Cost-Effectiveness Analysis of Etanercept and Adalimumab for Plaque Psoriasis not Associated with Arthritis
por: Ruano, Juan, et al.
Publicado: (2013)

Successful Treatment of Inflammatory Linear Verrucous Epidermal Nevus with Concomitant Psoriasis Using Etanercept
por: Saifaldeen, Reda Hesham, et al.
Publicado: (2018)

Economic Impact of Etanercept in Patients with Psoriasis and Psoriatic Arthritis in Spain: A Systematic Review
por: Puig, Lluís, et al.
Publicado: (2019)

Secondary Generalized Cutaneous Mucinosis Developed During Etanercept Treatment in a Patient with Psoriasis
por: Zhou, Xin, et al.
Publicado: (2022)

Epidemiology of Schistosomiasis in the People’s Republic of China, 2004
por: Zhou, Xiao-Nong, et al.
Publicado: (2007)

Latent Tuberculosis in Psoriasis Patients Planned for Systemic Therapy – A Prospective Observational Study
por: Neema, Shekhar, et al.
Publicado: (2021)

A Patient with Urinary Tract Tuberculosis During Treatment with Etanercept
por: Shibata, Shiho, et al.
Publicado: (2015)

Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study
por: Giunta, Alessandro, et al.
Publicado: (2016)

Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
por: van Muijen, Marloes E., et al.
Publicado: (2021)

Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice
por: van der Schoot, L.S., et al.
Publicado: (2023)

Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway
por: Li, Shu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5mauo36rs3i5drno9ugfo567hj